Vertex steps back from its partnership with CRISPR Therapeutics VCTX211 T1D stem cell therapy

Greetings, fellow investors! Welcome back to ShareTreck. I'm Raj, and today, I will talk briefly about a split by Viacyte from its relationship with CRSP for VCTX211, The other collaborations of CRSP with Vertex remain intact. Viacyte is a subsidiary of Vertex.

Please let me have your ideas and opinions as well. I have provided time stamps so you can jump to the right section.

JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.

   / @sharetreck  

Please subscribe:    / @sharetreck  

The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
Disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.